JP2016531872A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016531872A5 JP2016531872A5 JP2016517505A JP2016517505A JP2016531872A5 JP 2016531872 A5 JP2016531872 A5 JP 2016531872A5 JP 2016517505 A JP2016517505 A JP 2016517505A JP 2016517505 A JP2016517505 A JP 2016517505A JP 2016531872 A5 JP2016531872 A5 JP 2016531872A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- pgf2α
- analog
- uva
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 claims 3
- 150000003169 prostaglandin F2α derivatives Chemical class 0.000 claims 3
- HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 claims 2
- 238000002679 ablation Methods 0.000 claims 2
- 238000013532 laser treatment Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000002674 ointment Substances 0.000 claims 2
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 claims 2
- 231100000241 scar Toxicity 0.000 claims 2
- 230000000475 sunscreen effect Effects 0.000 claims 2
- 239000000516 sunscreening agent Substances 0.000 claims 2
- 238000013268 sustained release Methods 0.000 claims 2
- 239000012730 sustained-release form Substances 0.000 claims 2
- BYJAVTDNIXVSPW-UHFFFAOYSA-N tetryzoline Chemical compound N1CCN=C1C1C2=CC=CC=C2CCC1 BYJAVTDNIXVSPW-UHFFFAOYSA-N 0.000 claims 2
- 239000003981 vehicle Substances 0.000 claims 2
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 claims 1
- 208000032544 Cicatrix Diseases 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- WJAJPNHVVFWKKL-UHFFFAOYSA-N Methoxamine Chemical compound COC1=CC=C(OC)C(C(O)C(C)N)=C1 WJAJPNHVVFWKKL-UHFFFAOYSA-N 0.000 claims 1
- 206010040799 Skin atrophy Diseases 0.000 claims 1
- 238000010317 ablation therapy Methods 0.000 claims 1
- 230000001800 adrenalinergic effect Effects 0.000 claims 1
- 239000000533 adrenergic alpha-1 receptor agonist Substances 0.000 claims 1
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 claims 1
- 210000001691 amnion Anatomy 0.000 claims 1
- 229960002470 bimatoprost Drugs 0.000 claims 1
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 claims 1
- 229960003679 brimonidine Drugs 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 230000006835 compression Effects 0.000 claims 1
- 238000007906 compression Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 238000009093 first-line therapy Methods 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000003906 humectant Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 229960001160 latanoprost Drugs 0.000 claims 1
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 229960002342 mephentermine Drugs 0.000 claims 1
- RXQCGGRTAILOIN-UHFFFAOYSA-N mephentermine Chemical compound CNC(C)(C)CC1=CC=CC=C1 RXQCGGRTAILOIN-UHFFFAOYSA-N 0.000 claims 1
- 229960005192 methoxamine Drugs 0.000 claims 1
- 239000002077 nanosphere Substances 0.000 claims 1
- -1 nefazoline Chemical compound 0.000 claims 1
- 229960001528 oxymetazoline Drugs 0.000 claims 1
- 229960001802 phenylephrine Drugs 0.000 claims 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims 1
- 229920001296 polysiloxane Polymers 0.000 claims 1
- PXGPLTODNUVGFL-UHFFFAOYSA-N prostaglandin F2alpha Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CC=CCCCC(O)=O PXGPLTODNUVGFL-UHFFFAOYSA-N 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000037387 scars Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229960004458 tafluprost Drugs 0.000 claims 1
- WSNODXPBBALQOF-VEJSHDCNSA-N tafluprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COC1=CC=CC=C1 WSNODXPBBALQOF-VEJSHDCNSA-N 0.000 claims 1
- 229960000337 tetryzoline Drugs 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 229960002368 travoprost Drugs 0.000 claims 1
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims 1
- 229960000833 xylometazoline Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361960740P | 2013-09-26 | 2013-09-26 | |
| US61/960,740 | 2013-09-26 | ||
| PCT/IB2014/002746 WO2015044788A1 (en) | 2013-09-26 | 2014-09-26 | Prostaglandin f2alpha and analogues thereof for treating atrophic cutaneous scarring |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016531872A JP2016531872A (ja) | 2016-10-13 |
| JP2016531872A5 true JP2016531872A5 (enExample) | 2017-11-02 |
| JP6453318B2 JP6453318B2 (ja) | 2019-01-16 |
Family
ID=52282772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016517505A Expired - Fee Related JP6453318B2 (ja) | 2013-09-26 | 2014-09-26 | 委縮性皮膚瘢痕を治療するためのプロスタグランジンＦ２α及びその類似体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10039770B2 (enExample) |
| EP (1) | EP3049088B1 (enExample) |
| JP (1) | JP6453318B2 (enExample) |
| KR (1) | KR102221499B1 (enExample) |
| CN (1) | CN105658221B (enExample) |
| AU (1) | AU2014326298B2 (enExample) |
| BR (1) | BR112016006426A2 (enExample) |
| CA (1) | CA2924460A1 (enExample) |
| MX (1) | MX374476B (enExample) |
| RU (1) | RU2690183C2 (enExample) |
| WO (1) | WO2015044788A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6659819B2 (ja) * | 2015-07-09 | 2020-03-04 | ガルデルマ・ソシエテ・アノニム | 化学療法に関連する脱毛の軽減方法 |
| CN106929477B (zh) * | 2017-03-20 | 2020-01-10 | 江南大学 | 一株抗前列腺素F2α的特异性单克隆抗体杂交瘤细胞株WXX-2及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3278447A (en) | 1963-12-02 | 1966-10-11 | Cloro Bac Products Inc | Process for stabilizing chlorine dioxide solution |
| CA2003198C (en) | 1988-11-29 | 1995-03-21 | Anthony J. Dziabo, Jr. | Aqueous ophthalmic solutions and method for preserving same |
| US5736165A (en) | 1993-05-25 | 1998-04-07 | Allergan | In-the-eye use of chlorine dioxide-containing compositions |
| US6194415B1 (en) | 1995-06-28 | 2001-02-27 | Allergan Sales, Inc. | Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury |
| RU2195889C2 (ru) * | 1999-05-24 | 2003-01-10 | Парамонов Борис Алексеевич | Способ дермабразии |
| US6468989B1 (en) | 2000-07-13 | 2002-10-22 | Dow Pharmaceutical Sciences | Gel compositions containing metronidazole |
| US6387383B1 (en) | 2000-08-03 | 2002-05-14 | Dow Pharmaceutical Sciences | Topical low-viscosity gel composition |
| US7405274B2 (en) * | 2003-06-04 | 2008-07-29 | Fibrogen, Inc. | Connective tissue growth factor antibodies |
| EP2278993A4 (en) * | 2008-05-16 | 2012-09-12 | Corthera Inc | METHOD FOR PROMOTING HEALING |
| EP2389939A1 (en) * | 2010-05-28 | 2011-11-30 | Novagali Pharma S.A. | Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions |
| CN102031260A (zh) * | 2010-08-24 | 2011-04-27 | 苏州圣诺生物医药技术有限公司 | 促进皮肤伤口无疤痕愈合的siRNA及应用 |
| EP3178465A1 (en) * | 2010-12-06 | 2017-06-14 | Follica, Inc. | Methods for treating baldness and promoting hair growth |
| AU2012212481A1 (en) * | 2011-01-31 | 2013-08-22 | Allergan, Inc. | Method of enhancing hair growth |
| US20120251613A1 (en) * | 2011-03-29 | 2012-10-04 | Agila Specialities Pvt. Ltd. | Method for treating vitiligo with a prostaglandin analogue |
| WO2014179263A1 (en) * | 2013-04-30 | 2014-11-06 | Allergan, Inc. | Therapeutic agents |
-
2014
- 2014-09-26 BR BR112016006426A patent/BR112016006426A2/pt active Search and Examination
- 2014-09-26 WO PCT/IB2014/002746 patent/WO2015044788A1/en not_active Ceased
- 2014-09-26 CA CA2924460A patent/CA2924460A1/en not_active Abandoned
- 2014-09-26 US US15/021,789 patent/US10039770B2/en active Active
- 2014-09-26 MX MX2016003650A patent/MX374476B/es active IP Right Grant
- 2014-09-26 RU RU2016110925A patent/RU2690183C2/ru active
- 2014-09-26 EP EP14824091.4A patent/EP3049088B1/en active Active
- 2014-09-26 JP JP2016517505A patent/JP6453318B2/ja not_active Expired - Fee Related
- 2014-09-26 CN CN201480053306.1A patent/CN105658221B/zh not_active Expired - Fee Related
- 2014-09-26 KR KR1020167010897A patent/KR102221499B1/ko not_active Expired - Fee Related
- 2014-09-26 AU AU2014326298A patent/AU2014326298B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9642895B2 (en) | Peptides for enhancing transdermal delivery | |
| CA3033570C (en) | Topical film delivery system | |
| AR068816A1 (es) | Composiciones de brimonidina mejorada para el tratamiento del eritema | |
| MX2011008616A (es) | Peptidos utiles en el tratamiento y/o cuidado de la piel , mucosas y/o cuero cabelludo y su uso en composiciones cosmeticas o farmaceuticas. | |
| EA201200762A1 (ru) | Применение простагландинов f2-альфа и аналогов для заживления повреждений роговицы и конъюнктивы | |
| PH12012500756A1 (en) | Peptides used in the treatment and/or care of the skin, mucous membranes and/or hair and its use in cosmetic or pharmaceutical compositions | |
| JP2006117700A5 (enExample) | ||
| CN104159594A (zh) | 用于皮肤病治疗的凯莫瑞c15肽的局部制剂 | |
| BR112014015482A2 (pt) | compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática | |
| EA201500553A1 (ru) | Многодневный пластырь для чрескожного введения ротиготина | |
| BRPI0922789A2 (pt) | peptídeo de ligação de albumina intermediador para reconhecimento de doença | |
| BR112015005339A8 (pt) | uso de óleo de semente de fruta milagrosa como um ingrediente ativo | |
| JP5832302B2 (ja) | ケラチンへの局所薬剤デリバリーにおける表面活性タンパク質の組成物、使用及び使用方法 | |
| AR091724A1 (es) | Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica | |
| JP2015528479A5 (enExample) | ||
| BR112014002885A2 (pt) | uso de composto orgânico para o tratamento da síndrome de noonan | |
| RU2012149868A (ru) | Полисахарид семян для применения в лечении воспалительных заболеваний | |
| JP2016531872A5 (enExample) | ||
| EA201270747A1 (ru) | Композиции и способы для профилактики и лечения ран | |
| WO2009106715A3 (fr) | Peptide derive d'une proteine de la famille des aquaporines | |
| WO2015100348A8 (en) | Keloid reduction using topical allantoin | |
| RU2016110925A (ru) | Простагландин f2 альфа и его аналоги для лечения атрофического кожного рубцевания | |
| JP2017502089A5 (enExample) | ||
| CL2018003268A1 (es) | Ácidos carboxílicos para tratar/prevenir una enfermedad de la piel. | |
| JP2014517038A5 (enExample) |